About Wilmot Cancer Institute UR Medicine’s Wilmot Cancer Institute (WCI) features an 84-bed cancer center with 11 outpatient locations throughout the Rochester and Finger Lakes region. Wilmot, a component of Strong Memorial Hospital, offers patients and their families comprehensive services including one of upstate New York’s largest blood and marrow transplant programs and the Rochester area’s only ACOS-accredited breast cancer center. Wilmot is home to the region’s first survivorship clinic and offers clinical trials of new therapies and options that may not be available anywhere else upstate. In addition, Wilmot includes a team of scientists who investigate many aspects of cancer, with an emphasis on how best to provide precision cancer care. Established in 1974 as the University of Rochester Cancer Center, Wilmot Cancer Institute has its roots in an era that encouraged academic medical centers to bring their expertise in fields such as cancer to regional communities. Wilmot Cancer Institute has stayed true to that vision and, through its network of locations, provides patients and families comprehensive cancer care closer to where they live and work. The Wilmot Cancer Institute is named for James P. Wilmot, a prominent local businessman, philanthropist and leading member of the Rochester community. Wilmot created the Wilmot Foundation, which is dedicated to attracting, training and supporting doctors who are pursuing a career in cancer research. The Foundation provides fellowships to young medical doctors so they can pursue their research goals. Facts at a Glance In 2015, WCI provided care for more than 4,400 patients from across upstate New York. Outpatient clinic visits and procedures: 208,000 Inpatient admissions: 2,941 Over 100 physicians provide oncology care throughout the Institute. More than 200 registered nurses and nurse practitioners care for our patients. Director: Jonathan W. Friedberg, M.D., M.M.Sc. Co-director and Director of Research: Hartmut “Hucky” Land, Ph.D. Co-director and Director of Clinical Operations: David C. Linehan, M.D. Over 100 clinical trials are active and open for a wide range of cancers. $16 million in NCI grant funding.